3-乙炔苯基氨基甲酸叔丁酯 | 185619-66-3

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 3-乙炔苯基氨基甲酸叔丁酯
• 中文别名: 无
• 英文名称: tert-butyl (3-ethynylphenyl)carbamate
• 英文别名: (3-ethynyl-phenyl)-carbamic acid tert-butyl ester；N-Boc-3-ethynylaniline；Tert-butyl 3-ethynylphenylcarbamate；tert-butyl N-(3-ethynylphenyl)carbamate
• CAS: 185619-66-3
• 化学式: C₁₃H₁₅NO₂
• 分子量: 217.268
• InChiKey: OVWBYRQRBCBWDM-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.1
• 重原子数：
  16
• 可旋转键数：
  4
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.31
• 拓扑面积：
  38.3
• 氢给体数：
  1
• 氢受体数：
  2

安全信息

• 危险性防范说明：
  P280,P305+P351+P338
• 危险性描述：
  H302
• 储存条件：
  存储条件：2-8°C，干燥密封。

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
Product Name: tert-Butyl 3-ethynylphenylcarbamate
Synonyms:

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.

---

Section 3. Composition/information on ingredients.
Ingredient name: tert-Butyl 3-ethynylphenylcarbamate
CAS number: 185619-66-3

---

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Store in closed vessels, refrigerated.
Storage:

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
No data
Melting point:
Flash point: No data
Density: No data
Molecular formula: C13H15NO2
Molecular weight: 217.3

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  3-乙炔苯基氨基甲酸叔丁酯 在 cobalt(II) tetrafluoroborate hexahydrate 、 2,4,5,6-四(9H-咔唑-9-基)异酞腈 、 1,3-双(二苯基膦)丙烷 、 N,N-二异丙基乙胺 作用下， 以 乙腈 为溶剂， 反应 18.0h， 以83%的产率得到
  参考文献：
  名称：

  光化学钴催化的加氢炔基化反应生成1,3-烯炔

  摘要：

  据报道，使用钴催化和有机染料4CzIPN的金属光氧化还原方法进行了光化学加氢烷基化。该方案无需催化化学计量的金属还原剂即可实现催化反应，通常需要将较高氧化态的钴配合物转化为活性较高的较低氧化态的化学计量的金属还原剂。加氢烷基化可提供良好的高产率和E选择性的1,3-烯炔（25–99 ％的产率，17→> 99：1 E：Z（27个示例）。重要的是，通常也很少发生的末端炔烃的“交叉二聚化”，并且以异常高的立体选择水平发生。此外，据报道，大环加氢炔化反应具有良好的高收率，可提供大环烯炔基序，这些基序在许多具有生物活性的天然产物中都可以发现

  DOI：

  10.1021/acscatal.9b00248
• 作为产物：
  描述：

  二碳酸二叔丁酯 在 bis-triphenylphosphine-palladium(II) chloride 、 copper(l) iodide 、 四丁基氟化铵 、 sodium hydride 作用下， 以 四氢呋喃 、 苯 为溶剂， 反应 13.5h， 生成 3-乙炔苯基氨基甲酸叔丁酯
  参考文献：
  名称：

  Triazolo-β-aza-ε-amino acid and its aromatic analogue as novel scaffolds for β-turn peptidomimetics

  摘要：

  Triazolo-β-aza-ε-氨基酸及其芳香类似物（AlTAA/ArTAA）在肽骨架中标记了一类新型的构象受限分子支架，可诱导β-转角构象。这在Leu-enkephalin类似物和其他设计的肽中得到了证明。

  DOI：

  10.1039/c4cc08414d

文献信息

• MACROCYCLIC COMPOUNDS AND THEIR USE AS KINASE INHIBITORS
  申请人：Combs Andrew Paul

  公开号：US20090286778A1

  公开（公告）日：2009-11-19

  The present invention relates to macrocyclic compounds of Formula I: or pharmaceutically acceptable salts thereof or quaternary ammonium salts thereof wherein constituent members are provided hereinwith, as well as their compositions and methods of use, which are JAK/ALK inhibitors useful in the treatment of JAK/ALK-associated diseases including, for example, inflammatory and autoimmune disorders, as well as cancer.

  本发明涉及以下化学式I的大环化合物： 或其药用可接受盐或季铵盐，其中所述成员在此提供，并且它们的组成物和使用方法，这些JAK/ALK抑制剂在治疗JAK/ALK相关疾病中有用，例如炎症和自身免疫性疾病以及癌症。
• Click chemistry-based synthesis and anticancer activity evaluation of novel C-14 1,2,3-triazole dehydroabietic acid hybrids
  作者：Wei Hou、Zhi Luo、Guanjun Zhang、Danhui Cao、Di Li、Haoqiang Ruan、Benfang Helen Ruan、Lin Su、Hongtao Xu

  DOI：10.1016/j.ejmech.2017.07.049

  日期：2017.9

  exhibited obviously improved IC50 values ranging from 0.7 to 1.2 μM against a panel of tested cancer cells, but also showed very weak cytotoxicity on normal cells. Preliminary mechanism studies indicated that compound 24 could induce apoptosis in MDA-MB-231 cells and was worth developing into a novel natural product-like anticancer lead by proper structure modification.

  已经建立了一种简洁有效的合成方法，以中到高收率容易地获得一系列新颖的C-14 1,2,3-三唑系绳的脱氢松香酸衍生物。体外抗增殖活性评估表明，大多数杂种在低微摩尔至亚微摩尔IC 50值的多种癌细胞系中均表现出有效的抑制活性。进一步的研究表明，一些这些类似物如20，21，和24也针对在低浓度以剂量依赖性方式耐阿霉素MCF-7克隆有效。值得注意的是，最有效的化合物24具有3-（叔-丁氧基羰基氨基）苯基取代的三唑部分不仅对一组经过测试的癌细胞表现出明显改善的IC 50值，范围为0.7至1.2μM，而且对正常细胞的毒性也很弱。初步的机理研究表明，化合物24可以诱导MDA-MB-231细胞凋亡，通过适当的结构修饰，值得发展为新型的天然产物样抗癌药。
• Protein-tyrosine phosphatase inhibitors and uses thereof
  申请人：——

  公开号：US20040214870A1

  公开（公告）日：2004-10-28

  The present invention is directed to compounds of formula (I), 1 or a pharmaceutically suitable salt or prodrug thereof, which are useful for the selective inhibition of protein tyrosine phosphatase-1B (PTP1B), and are useful for the treatment of disorders caused by overexpressed or altered protein tyrosine phosphatase 1B.

  本发明涉及式(I)的化合物，或其药用适宜盐或前药，用于选择性抑制蛋白酪氨酸磷酸酶-1B（PTP1B），并且用于治疗由过度表达或改变的蛋白酪氨酸磷酸酶1B引起的疾病。
• [EN] GLUCOCORTICOID RECEPTOR AGONIST AND IMMUNOCONJUGATES THEREOF<br/>[FR] AGONISTE DU RÉCEPTEUR DES GLUCOCORTICOÏDES ET IMMUNOCONJUGUÉS DE CELUI-CI
  申请人：ABBVIE INC

  公开号：WO2017210471A1

  公开（公告）日：2017-12-07

  Provided herein are glucocorticoid receptor agonist immunoconjugates, glucocorticoid receptor agonists, and methods of using the same, e.g., to treat autoimmune or inflammatory diseases.

  提供的是糖皮质激素受体激动剂免疫偶联物、糖皮质激素受体激动剂以及使用它们的方法，例如，用于治疗自身免疫性或炎症性疾病。
• [EN] HDAC INHIBITORS AND THERAPEUTIC METHODS USING THE SAME<br/>[FR] INHIBITEURS D'HISTONE DÉSACÉTYLASES ET PROCÉDÉS THÉRAPEUTIQUES LES UTILISANT
  申请人：UNIV ILLINOIS

  公开号：WO2017040564A1

  公开（公告）日：2017-03-09

  Histone deacetylases inhibitors (HDACIs) and compositions containing the same are disclosed. Methods of treating diseases and conditions wherein inhibition of HDAC provides a benefit, like a cancer, a neurodegenerative disorder, a peripheral neuropathy, a neurological disease, traumatic brain injury, stroke, hypertension, malaria, an autoimmune disease, autism, autism spectrum disorders, and inflammation, also are disclosed

  组蛋白去乙酰化酶抑制剂（HDACIs）及其包含该抑制剂的组合物被公开。还公开了治疗疾病和状况的方法，其中抑制HDAC可带来益处，例如癌症、神经退行性疾病、周围神经病变、神经系统疾病、创伤性脑损伤、中风、高血压、疟疾、自身免疫疾病、孤独症、孤独症谱系障碍和炎症。